Understanding Secondary Liver Cancer, also known as metastatic liver cancer, requires accurate clinical documentation and medical coding. This resource provides information on diagnosis codes, including ICD-10-CM codes for secondary liver cancer, and best practices for healthcare professionals. Learn about symptoms, treatment options, and the importance of precise medical coding for liver metastases. Find key details on staging, prognosis, and palliative care related to secondary liver cancer for improved patient care and accurate medical records.
Also known as
Secondary malignant neoplasm of liver
Cancer that has spread to the liver from another site.
Secondary malignant neoplasm of other specified sites
Cancer spread to specified sites, including liver, when primary is unknown.
Disseminated malignant neoplasm
Cancer that has spread widely throughout the body, potentially including the liver.
Secondary malignant neoplasms
Cancers that have spread from a primary site to other parts of the body.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is the liver cancer primary?
When to use each related code
| Description |
|---|
| Secondary Liver Cancer |
| Hepatocellular Carcinoma |
| Cholangiocarcinoma |
Coding C78.7 (secondary liver cancer) without documenting the primary site leads to unspecified codes, impacting reimbursement and data quality. ICD-10-CM coding, CDI query, HCC coding.
Incorrectly coding both primary and secondary liver cancers can cause overcoding and inflated case-mix index. Medical coding guidelines, HCC risk adjustment, compliance audit.
Failing to capture the primary cancer site when coding for liver metastasis impacts treatment planning and cancer registry data. CDI specialist, medical record review, coding compliance.
Patient presents with signs and symptoms suggestive of secondary liver cancer, also known as metastatic liver cancer or liver metastasis. The patient's primary cancer diagnosis is [Document primary cancer type and site]. Presenting complaints include [Document specific complaints, e.g., abdominal pain, right upper quadrant pain, hepatomegaly, jaundice, fatigue, weight loss, ascites, nausea, vomiting, loss of appetite]. Physical examination revealed [Document relevant physical findings, e.g., palpable liver mass, abdominal tenderness, jaundice, ascites]. Laboratory findings include [Document relevant lab values, e.g., elevated liver enzymes (AST, ALT, ALP), elevated bilirubin, abnormal coagulation studies, elevated alpha-fetoprotein (AFP)]. Imaging studies, including [Specify imaging modality, e.g., abdominal ultrasound, CT scan of the abdomen and pelvis, MRI of the liver], demonstrate [Describe imaging findings, e.g., multiple hepatic lesions, heterogeneous liver parenchyma, evidence of portal vein thrombosis]. Based on the patient's history, physical examination, laboratory results, and imaging findings, the diagnosis of secondary liver cancer is established. Differential diagnoses considered included [List differential diagnoses, e.g., primary liver cancer, benign liver lesions, cirrhosis]. The patient's current performance status is [Document ECOG performance status]. Treatment options discussed include [Document treatment options discussed, e.g., systemic chemotherapy, targeted therapy, hepatic artery embolization, radiofrequency ablation, supportive care, palliative care, hospice]. The patient understands the risks and benefits of each option and has elected to proceed with [Document chosen treatment plan]. Follow-up is scheduled for [Date and time of follow-up]. Prognosis discussed with the patient and family. Referral to oncology, gastroenterology, and palliative care as appropriate. This documentation supports ICD-10 code C78.7 (Secondary malignant neoplasm of liver and intrahepatic bile ducts) and appropriate CPT codes for evaluation and management, imaging studies, and procedures performed.